Genomic Vision makes Quest first commercial partner for molecular combing tech
This article was originally published in Clinica
French molecular diagnostics specialist Genomic Vision struck its first commercial deal, enlisting Quest Diagnostics as a partner to develop and sell tests based on its "revolutionary" molecular combing technology. The deal will run for five years with an option to renew after this time. Financial details were not disclosed.